Moreover, therapeutic targeting of CtBP2 in CKP mice with the small-molecule CtBP inhibitor 4-Cl-HIPP, resulted in reduced tumor burden similar to that induced by standard gemcitabine, with the combination synergistically attenuating tumor growth. The gene discussed is CTBP2; the disease is neoplasm.